Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?-Reference-Cited by-同舟云学术

Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?

Published:2023-05-20 Issue:15 Volume:41 Page:2713-2717
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Tannock Ian F.¹²^ORCID,Goldstein Daniel A.²³⁴⁵^ORCID,Ofer Jonathan³^ORCID,Gyawali Bishal⁶^ORCID,Meirson Tomer³^ORCID

Affiliation:

1. Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

2. Optimal Cancer Care Alliance, Ann Arbor, MI

3. Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel

4. Clalit Health Service, Tel Aviv, Israel

5. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

6. Division of Cancer Care and Epidemiology, Departments of Oncology and Public Health Sciences, Queen's University Cancer Research Institute, Kingston, Ontario, Canada

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00280

Reference25 articles.

1. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006

2. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis

3. Informative censoring — a neglected cause of bias in oncology trials

4. Inappropriate censoring in Kaplan-Meier analyses

5. Informative censoring of surrogate end-point data in phase 3 oncology trials

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial;European Urology;2024-09

2. Results of the TARGET-TP Randomized Clinical Trial;JAMA Oncology;2024-07-01

3. Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial;European Urology;2024-05

4. Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials;BMJ Oncology;2024-04

5. Adjuvant Therapy in Renal Cell Cancer;Kidney Cancer;2024-01-22